31 results on '"VON PAWEL, JOACHIM"'
Search Results
2. An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer
3. The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial
4. Randomized, Double-Blind, Phase II Trial Comparing Gemcitabine-Cisplatin plus the LTB4 Antagonist LY293111 versus Gemcitabine-Cisplatin plus Placebo in First-Line Non–Small-Cell Lung Cancer
5. Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer
6. Safety and Resource Utilization by Non-small Cell Lung Cancer Histology: Results from the Randomized Phase III Study of Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin in Chemonaïve Patients with Advanced Non-small Cell Lung Cancer
7. Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
8. Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program
9. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer
10. Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study
11. PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses
12. P3.02b-045 Patritumab plus Erlotinib in EGFR Wild-Type Advanced Non–Small Cell Lung Cancer (NSCLC): Part a Results of HER3-Lung Study
13. P1.07-003 A Phase II Study Evaluating the Combination of Everolimus with Carboplatin/Paclitaxel as 1st Line Treatment in Patients with Advanced LCNEC
14. PRS-03: Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
15. P3-155: De–novo–induction of lasting cranial remission in previously irradiated and pretreated patients with metastatic non–small–cell lung cancer
16. A1-06: Randomized multicenter german trial of surgery plus radiotherapy versus tri-modality treatment of operable stage IIIA NSCLC - long-term follow-up results
17. P3-098: Multicenter, randomized phase II trial of CI–1033, an irreversible pan– erbB inhibitor, for previously treated advanced non–small cell lung cancer
18. C1-06: BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)
19. B1-03: Phase II double blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC)
20. P3-116: Phase II study of DMXAA (AS1404) 1800 mg/m2 combined with carboplatin and paclitaxel in non-small cell lung cancer
21. C5-03: Open-label study of pemetrexed alone or in combination with a platinum for previously treated patients (pts) with malignant pleural mesothelioma (MPM): Outcomes from the International Expanded Access Program (EAP)
22. ANTIANGIOGENIC-SPECIFIC ADVERSE EVENTS (AES) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NINTEDANIB (N) AND DOCETAXEL (D).
23. PATIENT-REPORTED OUTCOMES FROM THE LUMELUNG 1 TRIAL: A RANDOMISED, DOUBLE-BLIND, PLACEBOCONTROLLED PHASE III STUDY IN SECOND-LINE ADVANCED NSCLC PATIENTS.
24. De-novo-induction of lasting cranial remission in previously irradiated and pretreated patients with metastatic non-small-cell lung cancer.
25. Open-label study of pemetrexed alone or in combination with a platinum for previously treated patients (pts) with malignant pleural mesothelioma (MPM): Outcomes from the International Expanded Access Program (EAP).
26. BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC).
27. Phase II double blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC).
28. Phase II study of DMXAA (AS1404) 1800 mg/m2 combined with carboplatin and paclitaxel in non-small cell lung cancer.
29. Multicenter, randomized phase II trial of CI-1033, an irreversible pan- erbB inhibitor, for previously treated advanced non-small cell lung cancer.
30. Randomized multicenter german trial of surgery plus radiotherapy versus tri-modality treatment of operable stage IIIA NSCLC - long-term follow-up results.
31. Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.